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STRIKING THE BALANCE: PHARMACEUTICAL
PATENT VALUES AND CONSUMER

AvAABLITY

By Valerie Sarigumba

Pharmaceutical

have long benefited from laws allowing
extensive patentcompanies,
protection("Brands")
on their
products. The Brands assert that pharmaceutical
patent laws protect their products' value, resulting
in profits that allow the Brands to continue
developing new drugs. Furthermore, Brands
argue, it is necessary to protect these profits due
to the high cost of bringing new drugs to the
market.
However, companies producing generic
versions of the Brands' pharmaceuticals
("generics") hold that the current patent laws
prevent cheaper, but identical, versions of
pharmaceuticals from reaching the consumers in
a timely manner. All three branches of the federal
government have been wrestling with this issue
to find the balance between protecting and
promoting pharmaceutical innovation while
upholding consumer interests.

&

In 1984, Congress passed the Drug
Price Competition
Patent Term Restoration
Act,
as
known
commonly
"Hatch-Waxman."
Drug Price Competition & Patent Term
Restoration Act, Pub.
L. No. 98-417, 98
Stat. 1585 (1984).
According to Christopher T. Griffith, an
intellectual property
attorney with Leydig
Voit & Mayer, Ltd. in
Chicago, "The underPAGE 15
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lying purpose behind Hatch-Waxman was an
effort to strike a balance between the interests of
the generic companies and the Brands." HatchWaxman shortened approval for generic versions
of Brand drugs by creating the Abbreviated New
Drug Application ("ANDA"). The act also
allowed generics to develop their own version of
a Brand drug while it was still under patent. While
for any other industry this practice would
constitute patent infringement, it allowed generics
to be released into the market as soon as the
Brand's patent expired.
ANDA rules provide several routes for
marketing generic drugs, but one particular route,
Paragraph IV certification, is used when the
patent has not expired but the generic claims that
the patent is invalid or that its own product does
not infringe upon the patent. However, Paragraph
IV also leads to an elaborate litigation chess game
between the generics and the Brands to protect

"The FDA proposal asserts
that innovation will not be
infringed upon because
Brands will still be free to
litigate patent infringements... However, [b]rands
must dedicate significant time,
energy, and money to court
battles, all of which could
otherwise be spent developing
new pharmaceuticals."
PUBLIC INTEREST LAW REPORTER

the intellectual property
and marketing rights for
the drug at issue.
THE

MARKETING

ExcLusivrrv
PERIOD

he first generic
to file the

ANDA
with respect to a
particular Brand's drug
using Paragraph IV becomes
eligible for an exclusive
180-day marketing
period. During this
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time, the Food and Drug Administration ("FDA")
may not approve any other ANDAs on that drug.
This exclusivity period promises huge profits for
the first-filing generic.
To be able to take advantage of Paragraph
IV's exclusivity period, the generics aim to
develop drugs with the same function as the
Brand's drug but with enough differences to
distinguish the generic version from the patentprotected Brand version. In the vast majority of
cases though, the Brand responds to the
Paragraph IV ANDA filing by suing the generic
for patent infringement.

The

THE 30-MONTH STAY

Brand's patent infringement suit
automatically triggers a 30-month stay.
During the 30-month stay, the FDAmay
not act on the Paragraph IV ANDA filed by the
generic. Additionally, under the current law, the
Brand may eventually get more than one 30month stay.
To further explore what this entails, it is
important to know how the Brand's patents are
initiated. The Brand's patents are listed in the
FDA's Orange Book. The Orange Book is the
common name for the FDA publication entitled,
"Approved Drug Products With Therapeutic
Equivalents Evaluations," which lists the patents
claiming a drug or method of using a drug. As
the Brand makes improvements or changes to
the drug, the Brand can patent these changes and
list them in the Orange Book. Because the FDA
has no authority to review patents to determine
their validity, it has to list them. This allows the
Brand to patent new changes when the old
patents expire. Then, the Brand can get multiple
30-month stays-a new stay for each new
patent-in response to a generic's Paragraph IV
ANDA.

Faced

AGREEMENTS NOT TO MARKET

with a patent challenge, the Brand
may take an additional step outside the
normal Hatch-Waxman litigation

PAGE 16
http://lawecommons.luc.edu/pilr/vol8/iss1/6

process. According to a study issued in July,
2002 by the Federal Trade Commission
("FTC"), Brands have pursued settlement
agreements with generics. Generic Drug Entry
Prior to Patent Expiration: An FTC Study, at
h ttp : w w w. ftc. go v/o s/2 002/07/
genericdrugstudy.pdf (July, 2002). For
example, a generic that gets the 180-day
exclusivity period may agree to a settlement with
the Brand, in which the generic refrains from
marketing its version of the drug in exchange for
a significant payment. The FTC study
recommended that Brands should file such
settlement agreements with the FTC. This point
was included in a recent legislative move by the
Senate to alter Hatch-Waxman.

In

LEGISLATiVE AcoN
July 2001 the Senate approved the Great-

er Access to Affordable Pharmaceuticals Act ("GAAP"), brought by Senators John McCain (R-AZ) and Charles
Schumer (D-NY). S. 812, 1071 Cong. (2001).
Besides requiring Brands to file settlements with
the FTC, the GAAP also allows for only one
30-month stay. Thus, the 30-month stay would
no longer apply to every new Brand patent for a
particular drug. Instead, the Brand would only
be granted a 30-month injunction against the
generic when the generic gets a Paragraph IV
certification for a patent listed within 30 days after
the Brand's New Drug Application ("NDA") is
approved. Furthermore, the Brand would not
receive a 30-month stay for Paragraph IV
certifications against later Brand patents. Rather,
to protect new patents, the Brand would have to
seek a preliminary injunction from the court
against the generic, and then it would wait until
the court determines whether or not the Brand's
new patent is valid.
Another change in the GAAP from
Hatch-Waxman is that the Brand would have to
bring an infringement action within 45 days of
the generic providing notice to the Brand that it
filed a Paragraph IV ANDA. If the Brand fails
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to do so, the Brand is then barred from bringing
the action.
The future of the GAAP is uncertain, as
it remains in the House after being referred to the
House Subcommittee on Health in June, 2001,
but the make-up of Congress has since changed.
H.R. 1862, 1 0 7 th Cong. (2001). President
George W. Bush, however, has joined the

"The

underlying purpose
behind Hatch- Waxman was an
effort to strike a balance
between the interests of the
generic companies and the
Brands."
-

Intellectual Property Attorney

Christopher T Griffith, Leydig
Voit & Mayer, Ltd.
movement to alter the provisions of HatchWaxman.

In

STATEMENTS BY THE PRESIDENT IN
SUPPORT OF CHANGE

an October 2002 statement, President

Bush recognized the need to balance
intellectual property rights while ensuring
that consumers were not overpaying for needed
pharmaceuticals. PresidentGeorge W Bush,
Remarks on PrescriptionDrugs at The Rose
Garden(Oct. 21, 2002) (transcript available at
http://www.whitehouse.gov/news/releases/
2002/10/20021021-2.html). The President
referred to the FTC study that asserted that
Brands were manipulating Hatch-Waxman in
order to protect patents at the expense of
consumers. Additionally, President Bush backed

a proposal about to be issued by the FDA
containing similar features as the GAAP.
Applications for FDA Approval to Market a
New Drug, 67 Fed. Reg. 65447 (proposed Oct.
24,2002). The FDA proposal would present a
list of patents that should not be issued, such as
those for product packaging and the addition of
intermediates. (Intermediates are materials
produced during the processing of the Brand's
active pharmaceutical ingredient but are not
present in the final drug product.) The proposal
would also limit the number of 30-month stays
to one.

STATEMENTS

FROM THE COURTS

e the FDA's proposal would allow
the FDA to determine what does
and does not establish a valid patent,
the courts have disagreed with this position.
Specifically, the Fourth Circuit has declared that
"the FDA has no expertise in making patent law
judgments." aaiPharmav. Thompson, 296
F.3d 227 (4th Cir. 2002). Furthermore, courts
have not been hesitant to protect Brand patents.
(See Astra Aktiebolag v. Andrx Pharmaceuticals, Inc., 222 F.Supp.2d 423.)

THE ARGUMENT

B

FOR PROTECTING

INNOVATION

rands argue that patents promote
innovation in the pharmaceutical industry.
In his statement, President Bush even
acknowledged that it can cost as much as $800
million to bring a new drug to the market.
Additionally, the patent on a new Brand is filed
when it is first developed. The Brand may
undergo years of testing before getting FDA
approval to market the drug, which often comes
close to the patent's expiration date. As a result,
the Brand's opportunity to realize a return on its
efforts is significantly diminished, unless some kind
of patent extension is achieved.
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